Drugs / Papaverine
Papaverine
also known as
Papaverine Hydrochloride · Artegodan · Cardoverina · NSC-136630 · NSC-35443 · Papaver hcl · papaverine HCL · Papaverini hydrochloridum · +2 more
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03064282 | Jun → Sep 2021 | prostate disorder | Manchanda Medical Clinic | Unknown | No outcome recorded |
| Phase 0 | NCT01813955 | Jun 2011 → May 2013 | schizophrenia | University of Copenhagen | Terminated | No outcome recorded Stop: Enrollment |
| Phase 13 trials | ||||||
| Phase 1 | NCT06834126 | Apr 2025 → Sep 2028 expected | rectum adenocarcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05136846 | Dec 2021 → Dec 2026 expected | non-small cell lung carcinoma | Ohio State University Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03824327 | Feb 2019 → Aug 2026 overdue | non-small cell lung carcinoma | Ohio State University Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05861765 | May → Sep 2023 | coronary vasospasm | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04162834 | Nov 2019 → Apr 2021 | kidney cancer | Asan Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03894904 | Apr 2019 → Oct 2020 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07657741 | Aug 2026 → Dec 2027 expected | infectious disease with sepsis, vascular insufficiency disorder | First Affiliated Hospital of Wannan Medical College | Not yet recruiting | No outcome recorded |
| — | NCT07641543 | Jun 2026 → Jun 2027 expected | anal sphincter dysplasia | Dr Raneen Abu Shqara | Not yet recruiting | No outcome recorded |
| — | NCT07572461 | May 2026 → May 2027 expected | chemotherapy-induced neuropathy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| — | NCT07237880 | Apr 2025 → Apr 2027 expected | — | Hillel Yaffe Medical Center | Recruiting | No outcome recorded |
| — | NCT07826533 | Mar 2025 → Apr 2027 expected | preterm premature rupture of the membranes | Wolfson Medical Center | Recruiting | No outcome recorded |
| — | NCT00955929 | Aug 2009 → Dec 2020 | erectile dysfunction, penile cancer | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy9 trials | ||||||
| Phase 0 | NCT04030663 Comparator | Feb → Sep 2019 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02584686 Background | Oct 2015 → May 2016 | vasculogenic impotence | Cairo University | Completed | Met primary |
| Phase 2 | NCT00080808 Comparator | Aug 2001 → Jul 2006 | prostate cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT02711241 Comparator | Jun → Dec 2010 | gastroenteritis | Hadassah Medical Organization | Terminated | No outcome recorded |
| Phase 4 | NCT07517796 Comparator | Oct 2025 → Oct 2027 expected | preterm premature rupture of the membranes | Western Galilee Hospital-Nahariya | Recruiting | No outcome recorded |
| Phase 4 | NCT06550232 Comparator | Aug 2024 → Mar 2025 | — | Western Galilee Hospital-Nahariya | Completed | No outcome recorded |
| — | NCT06547437 Comparator | Sep 2024 → Sep 2025 overdue | — | Western Galilee Hospital-Nahariya | Not yet recruiting | No outcome recorded |
| — | NCT06919289 Comparator | Mar 2024 | peroneal neuropathy | US Neuropathy Centers | Completed | No outcome recorded |
| — | NCT05759364 Comparator | May 2023 → Apr 2024 | — | Western Galilee Hospital-Nahariya | Unknown | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Papaverine | “Intracavernous injections of a trimix combination (Papaverine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL) will be injected three times a week, and sildenafil 50mg...” NCT00955929 ↗22“papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery” NCT04162834 ↗ “20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine” NCT02584686 ↗ |
| Known as | Artegodan | ChEMBL registry synonym — accepted as the source's own label CHEMBL19224 ↗ |
| Known as | Cardoverina | ChEMBL registry synonym — accepted as the source's own label CHEMBL19224 ↗ |
| Known as | NSC-136630 | ChEMBL registry synonym — accepted as the source's own label CHEMBL19224 ↗ |
| Known as | NSC-35443 | ChEMBL registry synonym — accepted as the source's own label CHEMBL19224 ↗ |
| Known as | Papaver hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL19224 ↗ |
| Known as | papaverine HCL | “infiltration of 0.5 cc of papaverine HCL (30mg/ml) for a 15mg perineural infiltration” NCT06919289 ↗ |
| Known as | Papaverine Hydrochloride | “Drug: Papaverine Hydrochloride” NCT07641543 ↗ |
| Known as | Papaverini hydrochloridum | ChEMBL registry synonym — accepted as the source's own label CHEMBL19224 ↗ |
| Known as | Papaverinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL19224 ↗ |
| Known as | Vasorin | ChEMBL registry synonym — accepted as the source's own label CHEMBL19224 ↗ |
| Action | Inhibit | “papaverine, an inhibitor of the PDE 10 family” NCT01813955 ↗ |
| Modality | Small molecule | — CHEMBL19224 ↗ |
| Route | Other | “intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly” NCT00080808 ↗ |